I liked this statement...
"To date, the most promising of these biomarkers is uCTXII, which has been shown to predict clinically relevant OA knee progression based on combination of patient reported outcomes and radiographic progression"...
"Additionally, uCTXII has also been shown to predict total joint replacement of the knee and hip in the Calcitonin Trials".
Par Shareholders, gosh dang it...wouldn't it just dovetail so nicely if we could observe somehow.....somewhere...the influence on iPPS on CTXII and go one step beyond that and compare that to Placebo in a clinical setting?
Check the P values above...check the prognostic biomarker result seen so far. COMP is also up there in terms of key biomarkers....bring on 008 results...
research reports and media, page-3193
-
- There are more pages in this discussion • 1,111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 29.5¢ | $34.55K | 115.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 40478 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |